Search

Your search keyword '"Wu, Eric Q."' showing total 822 results
Start Over Author "Wu, Eric Q."
822 results on '"Wu, Eric Q."'

13. Response to: Alfred Sandrock, Wildon Farwell. Letter to the Editor, Comparisons Between Separately Conducted Clinical Trials: Letter to the Editor Regarding Dabbous O, Maru B, Jansen JP, Lorenzi M, Cloutier M, Guérin A, et al. Adv Ther (2019) 36(5):1164-76. doi:10.1007/s12325-019-00923-8

Author

Dabbous, Omar, Maru, Benit, Jansen, Jeroen P., Lorenzi, Maria, Cloutier, Martin, Guérin, Annie, Pivneva, Irina, Wu, Eric Q., Arjunji, Ramesh, Feltner, Douglas, and Sproule, Douglas M.

Published
2019
Full Text
View/download PDF

15. Investigation of Adverse‐Event‐Related Costs for Patients With Metastatic Breast Cancer in a Real‐World Setting

Author

Hurvitz, Sara, Guerin, Annie, Brammer, Melissa, Guardino, Ellie, Zhou, Zheng‐Yi, Viau, Dominick Latremouille, Wu, Eric Q, and Lalla, Deepa

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Oncology and Carcinogenesis, Cancer, Breast Cancer, Clinical Research, 6.1 Pharmaceuticals, Evaluation of treatments and therapeutic interventions, Aged, Breast Neoplasms, Bridged-Ring Compounds, Capecitabine, Costs and Cost Analysis, Deoxycytidine, Drug-Related Side Effects and Adverse Reactions, Female, Fluorouracil, Health Care Costs, Humans, Middle Aged, Neoplasm Metastasis, Taxoids, Breast neoplasms, Neoplasm metastasis, Drug-related side effects and adverse reactions, Costs and cost analysis, Oncology & Carcinogenesis, Oncology and carcinogenesis
Abstract

BackgroundExisting treatments for metastatic breast cancer (mBC) are often effective but can cause adverse events (AEs). This study aimed to identify AEs associated with chemotherapies commonly used in mBC treatment (phase 1) and to quantify the economic impact of these AEs (phase 2).Materials and methodsPatients in phase 1 had at least one claim for therapy for mBC, with at least one episode with single or multiple agents. The most common chemotherapy-related complications were identified using medical and pharmacy claims data. In phase 2, patients meeting study criteria were divided into four treatment cohorts by the line of treatment and chemotherapy received: first-line taxane-treated patients, second-line taxane-treated patients, first-line capecitabine-treated patients, and second-line capecitabine-treated patients. Average monthly AE-related health care costs per cohort were stratified by cost component. Total monthly costs per number of AEs were also calculated.ResultsOn average, patients in phase 1 (n = 1,551) had 2 episodes of treatment, with a mean duration of 131 days. The most frequently noted complications were anemia (50.7% of mBC treatment episodes), bilirubin elevation (26.4%), and leukopenia (24.8%). In phase 2, costs related to AEs were primarily driven by incremental inpatient, outpatient, and pharmacy costs. Increases in average monthly costs ranged from $854 (9.0%) to $5,320 (69.5%), according to cohort. Overall costs increased with increasing numbers of AEs.ConclusionChemotherapy-related AEs in patients with mBC are associated with a substantial economic burden that increases with the number of AEs reported.

Published
2014

16. Treatment Patterns and FLT3 Mutation Testing Among Patients with Acute Myeloid Leukemia in China: A Retrospective Observational Study.

Author

Gong, Benfa, Cheng, Li-Jen, Young, Christopher H, Krishnan, Prabhuram, Wang, Ying, Wei, Hui, Zhou, Chunlin, Wei, Shuning, Li, Yan, Fang, Qiuyun, Zhong, Jia, Wu, Eric Q, Mi, Yingchang, and Wang, Jianxiang

Subjects
ACUTE myeloid leukemia, PROTEIN-tyrosine kinases, GENETIC mutation, SCIENTIFIC observation, MEDICAL screening, PRELEUKEMIA
Abstract

Introduction: For acute myeloid leukemia (AML), prognosis is particularly poor in patients harboring FMS-like tyrosine kinase 3 (FLT3) gene mutations, though routine screening for these mutations at diagnosis has been shown to be insufficient. The understanding of the impact of FLT3 mutations on treatment decisions is limited. Methods: In this retrospective, observational study, we investigated the key epidemiological characteristics, treatment patterns and responses among adult patients with newly diagnosed (ND) AML in China, who initiated treatment from January 1, 2015, to December 31, 2019, or progressed to relapsed/refractory (R/R) AML by December 31, 2020. Results: Of the 853 ND AML patients included, 63.4% were screened for FLT3 status, and 20.1% tested positive (FLT3MUT) at initial diagnosis. Of 289 patients who progressed to R/R AML during the study period, 24.9% were screened at the diagnosis of R/R AML, and 19.4% tested positive; 20.5% of screened patients changed FLT3 status at first diagnosis of R/R AML. Initial treatment regimens or treatment responses did not seem to differ in patients with ND AML by FLT3 mutation status. In patients with R/R AML, there was an apparent difference in second-line treatment choices by FLT3 mutation status; however, the number of FLT3-mutated patients were limited to demonstrate any meaningful distinction. FLT3-mutated R/R AML was associated with shorter relapse time. Conclusion: Study findings showed that there was a lack of routine testing for FLT3 mutations at first diagnosis of R/R AML, and initial treatment decisions did not differ by FLT3 mutation status. Given the clinical burden of FLT3MUT, likelihood of FLT3 status changes, and emerging FLT3 inhibitors, further routine FLT3 screening is needed to optimize treatment of R/R AML. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results